Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.03.08.21253117v1 NCT04355247 -Eligible patients were those 21 years or older with a diagnosis of Covid-19 and oxygen saturation ≥91%. For patients to… Continue reading "(09 Mar 2021) Methylprednisolone- Survival at 28 days was 98.6%"
Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages https://www.medrxiv.org/content/10.1101/2021.03.04.21252167v1 The study was conducted from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment,… Continue reading "(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients"
Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study https://www.medrxiv.org/content/10.1101/2021.03.03.21252855v1 NCT04405999- In a single-center randomized open-label study medical staff managing patients with suspected and confirmed COVID-19 were enrolled and followed-up for 8 weeks. 50 participants without a… Continue reading "(08 Mar 2021) Bromhexine Hydrochloride-prophylactic treatment was not associated with a lower positive swab PCR test"
Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study https://www.medrxiv.org/content/10.1101/2021.03.03.21252509v1 NCT04463264- The objective of this study was to evaluate the efficacy and safety of Nitazoxanide in reducing the SARS-COV 2 viral… Continue reading "(04 Mar 2021) Nitazoxanide- significant viral load reduction ≥ 35% from baseline up to day 7 of treatment"
Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit https://doi.org/10.34172/aim.2021.22 There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of… Continue reading "(28 Feb 2021) Infliximab- 37 % mortality rate in Infliximab group compared to 62 % in control group"
Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study https://doi.org/10.1111/jcpt.13394 A total of 12 pregnant women were identified to have received tocilizumab during pregnancy in the two hospitals. Median gestational age at admission was 27.7 weeks… Continue reading "(28 Feb 2021) Tocilizumab- No detrimental effects for the mother and newborn"
A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 https://doi.org/10.1177/0885066621994057 A total of 262 patients were grouped as receiving usual care (n = 75), methylprednisolone dosed at least at 1mg/kg/day for >/= 3 days (n = 104),… Continue reading "(27 Feb 2021) Dexamethasone & Methylprednisolone- mortality was 42% lower in the methylprednisolone group"
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia https://doi.org/10.1056/NEJMoa2028700 NCT04320615 (COVACTA)- Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median… Continue reading "(26 Feb 2021) Tocilizumab- did not result in significantly better clinical status or lower mortality at 28 days"
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections https://doi.org/10.1155/2021/6685921 754 subjects participated in this study: 694 patients (92.4%) who… Continue reading "(26 Feb 2021) Antivirals- dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment"
Effect of in-hospital treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on mortality and complications in patients hospitalized for COVID-19: a large Spanish cohort study https://www.medrxiv.org/content/10.1101/2021.02.24.21252391v1 Between February and June 2020, 11,205 patients were included, with mean age… Continue reading "(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality"
